Mind the Gap - Update on Global TB Goals Artwork

The TBPod

The TBPod is a podcast for clinicians and policymakers caring for patients with tuberculosis. The podcasts present discussions with expert clinicians, researchers, policymakers and advocates about their work in the field of tuberculosis. Tuberculosis remains one of the leading causes of death worldwide, and is an important contributor to morbidity among migrants arriving in Australia and New Zealand. There are around 1300 reported cases of TB in Australia each year, and a further 300 in New Zealand. Included in these figures are cases of multi-drug resistant (MDR) TB which pose significant barriers to treatment and management of the disease. The Australian government has committed to the global elimination of TB by 2030, but to do so requires the development of innovative new strategies, based on high-quality research, that has national and international reach. These podcasts aim to engage and update those who are interested in the field of tuberculosis through discussions with leaders in the field of tuberculosis.

All Episodes

The TBPod

Mind the Gap - Update on Global TB Goals

June 01, 2023 • Actnet

Today I had the privilege of speak with Professor Christoph Lange, Secretary General of the Union, founding chairman of TBNet and is the clinical lead for the Unite4TB Consortium. Professor Lange spoke to us about where we're up to with our EndTB Goals. Professor Lange spoke about the significant barriers that remain, where our shortfalls have come, where our successes have arisen, and what exciting opportunities lay in the years ahead for tuberculosis.

REFERENCES
Lange, Christoph, et al. "Perspective for precision medicine for tuberculosis." Frontiers in Immunology 11 (2020): 566608

Lange, Christoph, et al. "Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement." (2014): 23-63.

Günther, Gunar, et al. "Relative cost of multidrug-resistant TB medicines in Europe." The international journal of tuberculosis and lung disease 27.5 (2023): 341-344.

Koehler, Niklas, et al. "Pretomanid-resistant tuberculosis." Journal of Infection 86.5 (2023): 520-524.

Domínguez, José, et al. "Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement." The Lancet Infectious Diseases 23.4 (2023): e122-e137.

Heyckendorf, Jan, et al. "Method for diagnosis and treatment monitoring and individual therapy end decision in tuberculosis infection." U.S. Patent Application No. 17/904,544

Villar-Hernández, Raquel, et al. "Tuberculosis: current challenges and beyond." Breathe 19.1 (2023)

Günther, Gunar, et al. "Availability and costs of medicines for the treatment of tuberculosis in Europe." Clinical microbiology and infection 29.1 (2023): 77-84

DiNardo, Andrew R., et al. "Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes." European Respiratory Journal 60.3 (2022).

Günther, Gunar, et al. "Cost and availability of drugs and treatment regimens and availability of drug resistance testing for tuberculosis in Europe." medRxiv (2022): 2022-02

Boeree, M. J., et al. "UNITE4TB: a new consortium for clinical drug and regimen development for TB." The International Journal of Tuberculosis and Lung Disease 25.11 (2021): 886

Lönnroth, Knut, N. Sarita Shah, and Christoph Lange. "State-of-the-art series on tuberculosis and migration." The international journal of tuberculosis and lung disease 20.10 (2016): 1280-1281.

DiNardo, Andrew R., et al. "Tuberculosis endotypes to guide stratified host-directed therapy." Med 2.3 (2021): 217-232.